Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed acute myeloid leukemia patients based on the peripheral blast clearance rate: A single‐arm, phase 2 trial (RJ‐AML 2014). Issue 1 (1st November 2021)

• Record Type: Journal Article
• Authors: Zhang, Yunxiang; Li, Xiaoyang; Weng, Xiangqin; Shen, Yang; Chen, Yu; Zheng, Yu; Zhao, Huijin; You, Jianhua; Mao, Yuanfei; Wang, Lining; Wu, Min; Sheng, Yan; Wu, Jing; Hu, Jiong; Chen, Qiusheng; Li, Junmin
• Is Part Of: American journal of hematology. Volume 97:Issue 1(2022)
• Page Start: 43
• Page End: 51
• Publication Date: 2021-11-01
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.26386
• Languages: English
• ISSNs: 0361-8609

Abstract

Abstract: Individualized chemotherapy, which is at the forefront of acute myeloid leukemia (AML) treatment, has moderately improved outcomes over the past decade. Monitoring the peripheral blood blast burden during induction by flow cytometry has shown significant value in the evaluation of treatment responses. Our previous study reported the day 5 peripheral blast clearance rate (D5‐PBCR) as an indicator of early treatment response, and D5‐PBCR (+) patients showed poor outcomes. We performed the present phase 2 trial of early intervention in D5‐PBCR (+) patients with homoharringtonine (HHT) introduced in the traditional induction regimen with anthracycline and cytarabine. The primary endpoint was complete remission (CR). This study enrolled 151 patients, 65 patients were D5‐PBCR (+) and 55 patients completed induction with HHT addition. The overall CR rate after one course of induction was 84.4%, with 87.5% and 80.0% for the D5‐PBCR (−) and D5‐PBCR (+) groups, respectively. The incidence of grade 3/4 adverse events was comparable between the two groups. At the median follow‐up of 53.1 months, median overall survival (OS) was not reached in the entire cohort, and median event‐free survival (EFS) was 42.2 months. Neither the OS nor EFS showed significant differences between the D5‐PBCR (−) and D5‐PBCR (+) groups. Compared to historical data, significant improvements in both OS ( p = .020) and EFS ( p = .020) were observed in the D5‐PBCR (+) group. In conclusion, optimization of induction chemotherapy with idarubicin and cytarabine according to D5‐PBCR is feasible in patients with newly diagnosed AML. The addition of HHT demonstrated a good efficacy and safety profile.